Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $44

Benzinga · 2d ago
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $42 to $44.